Geneva, Switzerland-based ObsEva says that it has closed a 32 million Swiss franc ($34.8 million) -A financing round, led by Sofinnova Partners and co-led by Sofinnova Ventures and Novo A/S.
Concurrently, ObsEva signed a licensing agreement with Germany’s Merck KGaA’s (MRK: DE) biotech unit, under which Merck Serono will grant ObsEva worldwide development and commercialization rights to certain of its compounds in the field of preterm labor. The details of the agreement are not being disclosed. The funding will allow ObsEva to undertake the development of these compounds.
As part of the deal, MS Ventures, the corporate venture capital fund of Merck Serono, has taken a minority equity stake in the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze